Effects of bepotastine ophthalmic: A Synthesis of Findings from 13 Studies

  1. Home
  2. Effects of bepotastine ophthalmic
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of bepotastine ophthalmic: A Synthesis of Findings from 13 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of bepotastine ophthalmic: A Synthesis of Findings from 13 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Bepotastine besilate ophthalmic solution is a newly approved second-generation topical antihistamine indicated for the treatment of allergic conjunctivitis. 5 It is a selective histamine H1-receptor antagonist and mast cell stabilizer with inhibitory effects on eosinophilic activity. 10 Research has shown that bepotastine besilate ophthalmic solution can reduce ocular itching and conjunctival hyperemia in patients with allergic conjunctivitis. 8 , 11 Bepotastine besilate ophthalmic solution has been shown to be effective in treating ocular itching associated with allergic conjunctivitis within 3 minutes of a conjunctival allergen challenge (CAC) and with a sustained duration of action of at least 8 hours. 6

Bepotastine besilate ophthalmic solution is more effective than other histamine H1-receptor antagonists in reducing vascular hyperpermeability in various animal models of allergic conjunctivitis. 12 This means that it is better at stopping the leaky blood vessels that cause swelling and redness in the eyes. In addition, bepotastine besilate has been shown to suppress eosinophil recruitment, which are a type of white blood cell that can contribute to allergic inflammation. 12 Bepotastine besilate has a rapid onset of action (within minutes), which makes it an effective treatment for allergic conjunctivitis. 7

Benefits and Risks

Benefit Summary

Bepotastine besilate ophthalmic solution is a safe and effective treatment for ocular itching associated with allergic conjunctivitis. 6 It has a rapid onset of action and a sustained duration of action. 13 , 6 Bepotastine besilate ophthalmic solution has also been shown to be effective in reducing ocular itching and conjunctival hyperemia. 8 , 11

Risk Summary

Bepotastine besilate ophthalmic solution is generally well-tolerated, but side effects can occur. The most common side effects are eye pain, stinging, and redness. If you experience any side effects, please consult with your doctor or pharmacist.

Comparison of Studies

Similarities Between Studies

Most studies have shown that bepotastine besilate ophthalmic solution is effective in reducing the symptoms of allergic conjunctivitis. 8 , 11 , 6 These studies have also shown that bepotastine besilate ophthalmic solution is generally safe and well-tolerated.

Differences Between Studies

There are some differences in the dosage of bepotastine besilate ophthalmic solution used in different studies. 8 , 11 Additionally, some studies have reported different side effects. 6 These differences may be due to factors such as study design and participant characteristics.

Consistency and Contradictions of Results

The results of studies on bepotastine besilate ophthalmic solution are generally consistent, showing that it is effective in reducing the symptoms of allergic conjunctivitis. 8 , 11 , 6 However, there are some contradictions in the reported side effects. 6 This may be due to differences in study design and participant characteristics. More research is needed to fully understand the potential side effects of bepotastine besilate ophthalmic solution.

Practical Applications

Bepotastine besilate ophthalmic solution is a promising treatment for allergic conjunctivitis. It is important to consult with your doctor or pharmacist to determine if bepotastine besilate ophthalmic solution is right for you. 6 They can help you understand the potential benefits and risks of the medication.

Limitations of Current Research

There are some limitations to current research on bepotastine besilate ophthalmic solution. For example, more research is needed on the long-term safety and effectiveness of the medication. 6 Additionally, research is needed on the effectiveness of bepotastine besilate ophthalmic solution in different types of allergic conjunctivitis.

Future Research Directions

More research is needed to fully understand the long-term safety and effectiveness of bepotastine besilate ophthalmic solution. 6 Additionally, more research is needed on the effectiveness of bepotastine besilate ophthalmic solution in different types of allergic conjunctivitis. More research should also investigate bepotastine besilate's potential efficacy in treating allergic rhinitis. 3

Conclusion

Bepotastine besilate ophthalmic solution is a promising treatment for allergic conjunctivitis. It has been shown to be effective in reducing the symptoms of allergic conjunctivitis, with a rapid onset of action and a sustained duration of action. 8 , 11 , 6 While more research is needed, bepotastine besilate ophthalmic solution may be a valuable treatment option for individuals with allergic conjunctivitis. Consult with your doctor or pharmacist to determine if this medication is right for you.

Literature analysis of 13 papers
Positive Content
13
Neutral Content
0
Negative Content
0
Article Type
5
1
1
4
12
1.

Efficacy and Toxicity Evaluation of Bepotastine Besilate 1.5% Preservative-Free Eye Drops Vs Olopatadine Hydrochloride 0.2% Bak-Preserved Eye Drops in Patients with Allergic Conjunctivitis.

Author: MariniMaría Cecilia, BerraMartín Lucas, GiradoFernada, AlberaPaula Alejandra, Del PapaMelina Sol, PasseriniMaría Silvia, AguilarAlejandro Javier

Improved ocular surface health
Reduced nasal itching
Reduced ocular itching
Reduced rhinorrhea
Reduced tearing

This clinical trial compared the efficacy and safety of bepotastine besilate 1.5% preservative-free (BB-PF) and olopatadine 0.2% BAK-preserved (OL-BAK) drops for allergic conjunctivitis. Both medications were effective, but BB-PF was superior in resolving non-ocular symptoms and was safer for the ocular surface.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.

Language : English

2.

Comparison of cytotoxicities and anti-allergic effects of topical ocular dual-action anti-allergic agents.

Author: KimSung Il, ParkChoul Yong, FordjuorGladys, LeeJong Heon, LeeJong Soo, LeeJi Eun

Alcaftadine
Anti-allergic effects
Ocular surface health
Ocular toxicity

This study found that alcaftadine, a topical ocular dual-action anti-allergic agent, showed the least cytotoxicity and best therapeutic effects compared to bepotastine besilate and olopatadine HCL.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis.

Author: CastilloMayret, ScottNeil W, MustafaMohammad Z, MustafaMohammed S, Azuara-BlancoAugusto

Allergic conjunctivitis treatment

Topical antihistamines, mast cell stabilizers, or a combination of treatments are standard treatments for allergic conjunctivitis, although there is clinical uncertainty about their relative efficacy and safety.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

6.

Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis.

Author: MeierEdward J, TorkildsenGail L, GowJames A, McNamaraTimothy R, GomesPaul J, WilliamsJon I,

Allergic conjunctivitis treatment

This report examines the reduction of ocular itching from two conjunctival allergen challenge (CAC) clinical trials comparing bepotastine besilate ophthalmic solution (BBOS) 1.5% to placebo in subjects with a history of allergic conjunctivitis. The study found that BBOS 1.5% was superior to placebo for reducing CAC-induced ocular itching.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Histamine and H1-antihistamines: celebrating a century of progress.

Author: SimonsF Estelle R, SimonsKeith J

H1-antihistamine efficacy
H1-antihistamine safety

This review discusses the history and progress of antihistamines, highlighting their clinical pharmacology, efficacy, and safety.

Historical ArticleA research paper that analyzes past events and developments using primary sources and examines them from a historical perspective.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.

Author: WilliamsJon I, KennedyKathryn S, GowJames A, TorkildsenGail L, AbelsonMark B, GomesPaul J, McNamaraTimothy R,

Conjunctival hyperemia relief
Ocular itching relief

Bepotastine besilate ophthalmic solutions 1.0% and 1.5% were found to be safe and effective for the treatment of ocular itching and conjunctival hyperemia in allergic conjunctivitis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate.

Author: WilliamsJon I, GowJames A, KlierSharon M, McCueShannon L, SalapatekAnne Marie F, McNamaraTimothy R

Antihistamine activity
Reduced sedation

Bepotastine besilate, a second-generation antihistamine, demonstrated favorable pharmacokinetic, pharmacologic, safety, and antihistamine properties in non-clinical studies. It also showed additional anti-allergic activity beyond histamine H1 receptor antagonism.

Evaluation StudyResearch that systematically evaluates the effectiveness of a particular program or policy. It measures its outcomes and provides important information for future decision-making.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge.

Author: TorkildsenGail L, WilliamsJon I, GowJames A, GomesPaul J, AbelsonMark B, McNamaraTimothy R,

Effective treatment
Symptom reduction

Bepotastine besilate ophthalmic solution reduced nonocular symptoms induced by a conjunctival allergen challenge (CAC) for at least 8 hours after instillation.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

11.

Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.

Author: MacejkoThomas T, BergmannMark T, WilliamsJon I, GowJames A, GomesPaul J, McNamaraTimothy R, AbelsonMark B,

Reduced ocular itching
Modest reduction in conjunctival hyperemia

Bepotastine besilate ophthalmic solutions 1.0% and 1.5% significantly reduced ocular itching induced by conjunctival allergen challenge (CAC) for at least 8 hours, but only modestly reduced conjunctival hyperemia.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.

Author: KidaTetsuo, FujiiAtsuko, SakaiOsamu, IemuraMasahito, AtsumiIkuyo, WadaTomoyuki, SakakiHideyuki

Allergic conjunctivitis treatment

Bepotastine besilate is a selective histamine H1 receptor antagonist that shows promise for the treatment of allergic conjunctivitis. It is more effective than other H1 antagonists in reducing vascular hyperpermeability and eosinophil infiltration in animal models of allergic conjunctivitis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.

Author: AbelsonMark B, TorkildsenGail L, WilliamsJon I, GowJames A, GomesPaul J, McNamaraTimothy R,

Allergic Conjunctivitis Treatment

Bepotastine besilate, a selective histamine H(1)-receptor antagonist, is being investigated as a potential ophthalmic medication for allergic conjunctivitis based on its effectiveness and tolerability in treating allergic symptoms.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.